Tg Therapeutics (TGTX) Cash & Equivalents (2011 - 2026)

Tg Therapeutics' Cash & Equivalents history runs 16 years deep, the most recent figure standing at $572.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 333.48% year-over-year to $572.8 million; the TTM figure through Mar 2026 stood at $572.8 million (up 333.48% YoY), while the FY2025 annual figure was $1.3 million, up 256.6% from the prior year.
• Cash & Equivalents was $572.8 million for Q1 2026 at Tg Therapeutics, up from $1.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $572.8 million in Q1 2026 to a low of $371000.0 in Q4 2024.
• Historically, Cash & Equivalents has averaged $122.6 million across 5 years, with a median of $97.0 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Cash & Equivalents plunged 99.6% in 2024, then surged 333.48% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $102.3 million in 2022, then slipped by 9.16% to $92.9 million in 2023, then slumped by 99.6% to $371000.0 in 2024, then soared by 256.6% to $1.3 million in 2025, then surged by 43195.54% to $572.8 million in 2026.
• The last three Cash & Equivalents figures came in at $572.8 million (Q1 2026), $1.3 million (Q4 2025), and $74.1 million (Q3 2025), per Business Quant data.